Moleculin Biotech Trading Up 0.4 %
NASDAQ:MBRX opened at $0.54 on Monday. The firm’s fifty day simple moving average is $0.47 and its 200 day simple moving average is $0.57. Moleculin Biotech has a twelve month low of $0.34 and a twelve month high of $1.65. The firm has a market capitalization of $16.10 million, a price-to-earnings ratio of -0.53 and a beta of 1.89.
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last posted its earnings results on Friday, August 11th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.08. During the same period last year, the business posted ($0.24) earnings per share. On average, analysts predict that Moleculin Biotech will post -0.94 earnings per share for the current year.
Institutional Inflows and Outflows
Moleculin Biotech Company Profile
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.
- Five stocks we like better than Moleculin Biotech
- Learn Technical Analysis Skills to Master the Stock Market
- MarketBeat Week in Review – 11/6 – 11/10
- Short Selling: How to Short a Stock
- Data giants MongoDB and Snowflake just got upgraded
- What Is Dividend Yield and How Do You Calculate It?
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.